Medical Director, Creticos Cancer Center
Oncology
Dr. Ann M. Mauer, MD
|
|
Give Review
Dr. Ann M. Mauer works in the field of Oncology. She studied medicine at Loyola University Chicago Stritch School of Medicine. She received 1 awards: "Regional Top Doctor". Mauer is a published doctor as well. She has 55 publications published. The latest was: Survivorship in childhood cancer: a case statement for enhancement of the role of the American Cancer Society. Task Force on Children and Cancer of the American Cancer... Doctor Ann M. Mauer, MD accepts all Medicare patients.
Publications
- Adjuvant chemotherapy in older women with early-stage breast Cancer.
- Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced Carcinoma of the esophagus or gastroesophageal junction.
- A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung Cancer.
- Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung Cancer.
- A phase II study of ABT-751 in patients with advanced non-small cell lung Cancer.
- Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Tr...
- Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung Cancer.
- The prognostic value of chromosome 7 polysomy in non-small cell lung Cancer patients treated with gefitinib.
- A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal Cancer.
- The role of cooperative groups in Cancer clinical trials.
- Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung Cancer.
- Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell Carcinoma of the head and neck.
- Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
- Phase I study of dose-dense alternating doublets in advanced non-small-cell lung Cancer.
- Detection of small cell lung Cancer bone marrow involvement by discontinuous gradient sedimentation.
- Adult and childhood Acute lymphocytic leukemia: are they different diseases?
- Survivorship in childhood Cancer: a case statement for enhancement of the role of the American Cancer Society. Task Force on Children and Cancer of the American Cancer...
- New directions in the treatment of Acute lymphoblastic leukemia in children.
- The biological basis of age in the determination of prognosis in Acute lymphoblastic leukemia.
- Acute lymphoblastic leukemia in a young adult.
- The importance of an isolated central nervous system relapse in children with Acute lymphoblastic leukemia.
- Psychosocial protocol for childhood Cancer. A conceptual model.
- First two cases of immune hemolytic Anemia associated with ceftizoxime.
- Therapeutic plasma exchange for the Acute management of the catastrophic antiphospholipid syndrome: beta(2)-glycoprotein I antibodies as a marker of response to therapy.
- A case study documenting the antiCancer activity of ZD1839 (Iressa) in the brain.
- Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood Leukemia given cranial radiation or parenteral ...
- Multimodality therapy for esophageal Cancer: an emerging role.
- Dosing of oral etoposide normalized for body surface area.
- Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung Cancer.
- ZD0473 treatment in lung Cancer: an overview of the clinical trial results.
- Phase I/II investigation of paclitaxel, ifosfamide and carboplatin for advanced non-small-cell lung Cancer.
- Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
- A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung Cancer.
- Clinical studies of docetaxel (Taxotere) and concomitant chest therapy.
- Ifosfamide-based three-drug combination regimens in non-small cell lung Cancer.
- A phase I trial of the oral platinum Analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest.
- Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced Carcinoma of the esophagus.
- Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
- A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung Cancer.
- A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung Cancer.
- A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung Cancer.
- A phase I study of STEALTH cisplatin (SPI-77) and vinorelbine in patients with advanced non small-cell lung Cancer.
- Combined modality therapy in non-small cell lung and esophageal Cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy.
- Paclitaxel/carboplatin plus ifosfamide in non-small cell lung Cancer.
- Phase I study of docetaxel with concomitant thoracic radiation therapy.
- Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung Cancer.
- A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck Cancer.
- Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung Cancer.
- A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck Cancer.
- A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung Cancer.
- Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung Cancer: a phase I study.
- A phase II trial of UFT and leucovorin in women 65 years and older with advanced breast Cancer.
- Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.
- Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.
Schools
Loyola University Of ChicagoStritch School Of Medicine
University Chicago Pritzker School
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
University of Chicago -
Loyola University Chicago Stritch School of Medicine
Hospital
-
Advocate Illinois Masonic Medical Center
Drug Facts
| NPI NUMBER | 1891705463 | |
| NPPES Provider LastName | MAUER | |
| NPPES Provider FirstName | ANN | |
| NPPES Provider ZIPCode | 606576708 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 741.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 39.0 | |
| Percent Opioid Claims | 5.26 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1891705463 |
| Last Name Of The Provider | MAUER |
| First Name Of The Provider | ANN |
| View All |
Similar Doctors
|
|
Dr. Marilyn G. Pearson, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley J. Borowicz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shuo Ma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marta Batus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica K. Altman, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ruta Rao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Oana C. Danciu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Denise A. Levitan, MD
This Doctor is OpenDoctor Recommended.
|